 Home > Biochemistry News > Biotechnology News > Reduce proteinuria index by 47.6%, innovative targeted therapy obtains clinical proof of concept for the first time

Reduce proteinuria index by 47.6%, innovative targeted therapy obtains clinical proof of concept for the first time

 Last Update: 2021-12-31
 Source: Internet
 Author: User

Tags

baclofen drug class

sodium positive negative

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 1, 2021, Vertex Pharmaceuticals announced that a phase 2 clinical trial of the oral small molecule APOL1 inhibitor VX-147 has obtained positive results

APOL1-mediated kidney disease is a chronic kidney disease caused by mutations in the APOL1 gene

Image source: Vertex's official website

The primary endpoint of this phase 2 clinical trial is the percentage change from baseline in patients' UPCR at week 13, and the secondary endpoints are drug safety and pharmacokinetics

▲The decrease of proteinuria index was observed in the early stage of VX-147 treatment, and it continued to decrease during the 13-week course of treatment (picture source: reference [1])

In terms of safety, there were no treatment discontinuations due to adverse events (AE) in the trial, and no serious adverse events thought to be related to the study drug

Reference materials:

[1] Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.